Brain protection strategies and nanomedicine /

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Sharma, H. S. (Hari Shanker) (Editor ), Sharma, Aruna, MD (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Amsterdam, Netherlands ; Cambridge, MA, United States : Elsevier, 2021.
Edición:First edition.
Colección:Progress in brain research ; v. 266.
Temas:
Brain > Diseases.
Brain > Diseases > Treatment.
Nanomedicine.
Brain Diseases
Cerveau > Maladies.
Cerveau > Maladies > Traitement.
Internet Resources.
Index not Present.
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Intro
  • Progress in Brain Research
  • Copyright
  • Contributors
  • Contents
  • Acknowledgments
  • Preface
  • References
  • Chapter 1: Histamine H3 and H4 receptors modulate Parkinson's disease induced brain pathology. Neuroprotective effects of ...
  • 1. Introduction
  • 1.1. Histaminergic system in the brain
  • 1.2. Histaminergic receptors in the brain
  • 1.3. Histamine in brain diseases
  • 1.3.1. Cognitive dysfunction and Alzheimer's disease
  • 1.3.2. Motor disorders and Parkinson's disease
  • 1.3.3. Schizophrenia
  • 1.3.4. Multiple sclerosis
  • 1.3.5. Sleep disorders
  • 1.3.6. Addictive disorders
  • 2. Histaminergic system alterations in Parkinson's disease
  • 2.1. Histamine concentration in PD
  • 2.2. Histaminergic nerve fibers in PD
  • 2.3. Histaminergic gene and receptors in PD
  • 2.3.1. HMT and HDC gene expression are altered in PD brain
  • 2.3.2. Histamine H3 and H4 receptor expression are altered in PD brain
  • 3. Our own investigations on histamine modulation of Parkinson's disease
  • 3.1. Methodological consideration
  • 3.1.1. Animals
  • 3.2. Animal model of PD
  • 3.3. Modulation of histaminergic agents
  • 3.3.1. Histamine H3 receptor inverse agonist BF2649
  • 3.3.2. Histamine H3 receptor antagonist and partial H4 receptor agonist clobenpropit
  • 3.3.3. Anti-histamine mouse monoclonal antibody
  • 3.3.4. TiO2 nanodelivery of pharmacological agents
  • 3.4. Parameters measured
  • 3.4.1. Physiological parameters
  • 3.4.2. Physiological variables
  • 3.4.3. Blood-brain barrier permeability
  • 3.4.3.1. Albumin immunohistochemistry
  • 3.4.4. Cerebral blood flow
  • 3.4.5. Brain edema formation
  • 3.5. Behavioral functions
  • 3.5.1. Rota Rod treadmill
  • 3.5.2. Immobility during forced swimming
  • 4.1.2. Physiological variables in MPTP model of PD
  • 4.1.2.1. Mean arterial blood pressure
  • 4.1.2.2. Arterial pH
  • 4.1.2.3. Arterial PaCO2
  • 4.1.2.4. Arterial PaO2
  • 4.1.2.5. Heart rate
  • 4.1.2.6. Respiration rate
  • 4.1.3. Behavioral parameters in MPTP model of PD
  • 4.1.3.1. Rota-Rod performance
  • 4.1.3.2. Forced swimming immobility
  • 4.1.4. Biochemical parameters of MPTP model of PD
  • 4.1.4.1. Tyrosine hydroxylase enzyme
  • 4.1.4.2. Dopamine
  • 4.1.4.3. DOPAC
  • 4.1.5. Hallmarks of biomarkers in MPTP model of PD
  • 4.1.5.1. ASNC
  • 4.1.5.2. p-tau

Ejemplares similares